CymaBay stock: buy or sell?
June 26th, 2019
Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases.
Should I buy CymaBay stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with CymaBay stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is CymaBay Therapeutics stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we gathered 8 ratings published for CBAY stock in the last 30 days. The general sentiment of these ratings is bullish for CBAY stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-11||Piper Jaffray Companies||Overweight||Market Perform|
CymaBay stock analysis
CymaBay Therapeutics eased a terrible -2.62% and closed at $6.68.
Shares of CymaBay ended today at $6.68 and eased a terrible -2.62%. Since price and SMA200d lines crossed down on June 11th, CBAY fell $-4.41 per share (-39.77%). Since SMA100d and SMA200d crossed up on May, CBAY price slid a -48.14%.
After boosting an amazing 11.17% in a week last week, CymaBay Therapeutics closed this week at $6.68 and plummed a frightening -5.52%.
Since price and 40-weeks moving average lines crossed down by mid June, CBAY fell $-4.83 per share (-41.96%). Stocks under the 40w moving average line are usually not recommended for average traders. Since early May when SMA20w and SMA40w crossed up, CBAY price slipped $-6.44 per share (-49.09%).
CymaBay stock price history
CymaBay stock went public on February 3rd, 2014 with a price of $5.001. Since then, CBAY stock grew a 33.60%, with an average of 6.70% per year. If you had invested right after CBAY's IPO a $1,000 in CymaBay stock in 2014, it would worth $336.00 today.
1: Adjusted price after possible price splits or reverse-splits.
CymaBay stock historical price chart
CBAY stock reached 52-week highs on July at $14.94, and all-time highs 2018-03-05 with a price of 15.59.
CymaBay stock price target is $14.00Nobody can reliably foresee how stock prices may evolve in the future. However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. You should not follow the analysts' CBAY stock price predictions in the hope that they will be met as they may be wrong and not met. We have 7 price targets for CymaBay Therapeutics stock posted in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-17||B. Riley||Set Price Target||n/a||$7.00||-|
|2019-6-11||Piper Jaffray Companies||Lowers Target||$30.00||$8.00||-73.3%|
|2019-4-23||Raymond James||Set Price Target||n/a||$18.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, CymaBay failed to meet the expectations of the analysts and posted a fatal EPS of $-0.32 per share when experts were expecting $-0.36.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual sales report draw of to $10.00 M dollars. , its profit margin (compared to revenues) to -275.57%, that is $-27.56 million.
|2017||$10 M||-||$-27.56 M-275.6%||-|
Quarterly financial resultsReported quarter earnings marked $-19.45 M with a profit margin of . Profit margin remained stable a 0.00% compared to previous quarter when profit margin was inf%. When comparing revenues to same quarter last year, CymaBay sales marked a spooky correction and plummed a -100.00%. Looking back to recent quarterly results, CymaBay posted 4 negative quarters in a row.
|2017-Q1||$4.79 M||-||$-5.35 M-111.7%||-|
|2017-Q4||$5.21 M||8.71%||$-5.04 M-96.9%||-5.74%|
CymaBay ownershipWhen you are planning to buy a company, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CymaBay Therapeutics, 0.74% of all outstanding shares are owned by its staff.
Bearish positions for CBAY stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to CymaBay:
|Market cap||$458.9 M||$73.7 B||$242.9 B||$2.4 B||$2.2 B|
|Total shares||68.7 M||1,640.0 M||5,550.0 M||58.4 M||56.4 M|
|Float shares||53.9 M||1,630.0 M||5,520.0 M||56.8 M||45.7 M|
|- Institutional holdings (%)||88.5%||75.0%||76.2%||85.6%||85.8%|
|- Insider holdings (%)||0.7%||0.1%||0.0%||2.7%||13.4%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Wednesday, June 26th, 2019|
|Day range||$6.62 - $7.01|
|Average true range||$1.09|
|50d mov avg||$11.09|
|100d mov avg||$11.51|
|200d mov avg||$10.64|
CymaBay performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We compared CymaBay Therapeutics against Bristol-Myers Squibb, Pfizer, PTC Therapeutics and Xencor in the following table: